Multi-Gene Vascular Systems Ltd.
Records under this name other than patents Multi-Gene Vascular Systems Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Multi-Gene Vascular Systems Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,943,590 | Compositions and methods for treating ophthalmic disorders Lapsed on the fee record Ended May 17, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 17, 2023 | From the USPTO record |
| US 7,887,581 | Methods of hemodialysis utilizing grafts coated with cells expressing human fibulin-5 Term ended Term ended Dec 22, 2022 · From the USPTO record | Term ended | Term ended Dec 22, 2022 | From the USPTO record |
| US 7,767,201 | Vascular cells genetically altered to over-express angiogenic proliferation and maturation factors; treatment of atherosclerosis using same Lapsed on the fee record Ended Aug 3, 2022 · From the USPTO record | Lapsed on the fee record | Ended Aug 3, 2022 | From the USPTO record |
| US 8,022,195 | Vectors encoding cell growth and adhesion factors for simultaneous growth and adhesion of cells Term ended Term ended Nov 2, 2021 · From the USPTO record | Term ended | Term ended Nov 2, 2021 | From the USPTO record |
| US 7,175,658 | Artificial vascular grafts, their construction and use Term ended Term ended Nov 12, 2020 · From the USPTO record | Term ended | Term ended Nov 12, 2020 | From the USPTO record |
| US 7,563,278 | Drug-eluting intravascular prostheses and methods of use Term ended Term ended Sep 1, 2020 · From the USPTO record | Term ended | Term ended Sep 1, 2020 | From the USPTO record |
| US 7,364,725 | Endothelial cells engineered to express or overexpress fibulin-5 and a growth factor Lapsed on the fee record Ended Apr 29, 2020 · From the USPTO record | Lapsed on the fee record | Ended Apr 29, 2020 | From the USPTO record |